Discounted Cash Flow (DCF) Analysis Levered
Plus Therapeutics, Inc. (PSTV)
$3.52
-0.12 (-3.30%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Projected | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Revenue | 6.65 | 7 | 0.30 | 0.17 | 0.09 | 0.05 | 0.03 | 0.01 | 0.01 | 0 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (%) | ||||||||||
| Operating Cash Flow | -11.97 | -5.91 | -8.43 | -10.28 | -12.97 | -2.34 | -1.28 | -0.70 | -0.38 | -0.21 |
| Operating Cash Flow (%) | ||||||||||
| Capital Expenditure | -0.13 | -0.07 | -0.49 | -0.14 | -0.51 | -0.08 | -0.04 | -0.02 | -0.01 | -0.01 |
| Capital Expenditure (%) | ||||||||||
| Free Cash Flow | -12.11 | -5.97 | -8.93 | -10.42 | -13.48 | -2.42 | -1.33 | -0.73 | -0.40 | -0.22 |
Weighted Average Cost Of Capital
| Share price | $ 3.52 |
|---|---|
| Beta | 0.393 |
| Diluted Shares Outstanding | 26.26 |
| Cost of Debt | |
| Tax Rate | 0.00 |
| After-tax Cost of Debt | 38.25% |
| Risk-Free Rate | |
| Market Risk Premium | |
| Cost of Equity | 5.569 |
| Total Debt | 1.86 |
| Total Equity | 92.42 |
| Total Capital | 94.28 |
| Debt Weighting | 1.97 |
| Equity Weighting | 98.03 |
| Wacc |
Build Up Free Cash Flow
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Projected | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Revenue | 6.65 | 7 | 0.30 | 0.17 | 0.09 | 0.05 | 0.03 | 0.01 | 0.01 | 0 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -11.97 | -5.91 | -8.43 | -10.28 | -12.97 | -2.34 | -1.28 | -0.70 | -0.38 | -0.21 |
| Capital Expenditure | -0.13 | -0.07 | -0.49 | -0.14 | -0.51 | -0.08 | -0.04 | -0.02 | -0.01 | -0.01 |
| Free Cash Flow | -12.11 | -5.97 | -8.93 | -10.42 | -13.48 | -2.42 | -1.33 | -0.73 | -0.40 | -0.22 |
| WACC | ||||||||||
| PV LFCF | -11.07 | -13.48 | -2.28 | -1.17 | -0.61 | -0.31 | -0.16 | |||
| SUM PV LFCF | -4.53 |
Terminal Value
| Growth in perpetuity method: | |
|---|---|
| Long-term growth rate | |
| WACC (%) | 6.21 |
| Free cash flow (t + 1) | -0.22 |
| Terminal Value | -5.27 |
| Present Value of Terminal Value | -3.90 |
Intrinsic Value
| Enterprise Value | -8.43 |
|---|---|
| Net Debt | -16.26 |
| Equity Value | 7.83 |
| Shares Outstanding | 26.26 |
| Equity Value Per Share | 0.30 |